Last updated: 2026-10-13 23:14:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Nuvalent, Inc. (NUVL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Nuvalent, Inc. (NUVL) is trading at $-- in after-hours trading as of --, -- from the regular-session close of $--.
After-hours trading shows how investors are pricing NUVL after the regular session closes. The current after-hours price is -- the regular-session close, indicating -- after-hours sentiment.
Over the past seven days, Nuvalent, Inc. (NUVL) moved from $123.70 to $123.96, representing a gain of 0.21% ($0.26).
The stock traded between $123.55 and $123.99 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 1.92 million shares, up versus the previous seven-day period, indicating higher trading activity.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 228 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nuvalent, Inc. (NUVL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.